2011-06-13
Affibody to Present at Next Generation Protein Therapeutics Summit in San Francisco
Affibody AB will give a presentation titled “From Clinical Imaging to Serum Half-life Extension Using HER2-Specific Affibody Molecules” at Next Generation Protein Therapeutics Summit, taking place June 20-22, 2011 in San Francisco, California.
Ass. Prof Fredrik Frejd will give the presentation at 2pm on Monday June 20 in the track: “Beyond Antibodies”. Dr. Frejd will also participate in a panel discussion entitled “Half-Life Extension Strategies for Protein Therapeutics” at 2pm on Wednesday June 22 in the track: Protein Engineering & Design”
About Affibody
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.
Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.
Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.
Further information can be found at: www.affibody.se.